Immunotherapy in prostate cancer

Curr Urol Rep. 2015 Jun;16(6):34. doi: 10.1007/s11934-015-0509-7.

Abstract

Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic
  • Docetaxel
  • Humans
  • Immunotherapy*
  • Ipilimumab
  • Male
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / therapy*
  • Taxoids / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Cancer Vaccines
  • Ipilimumab
  • PROSTVAC
  • Taxoids
  • Docetaxel